Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation

被引:46
作者
Fahrleitner, A
Prenner, G
Leb, G
Tscheliessnigg, KH
Piswanger-Sölkner, C
Obermayer-Pietsch, B
Portugaller, HR
Berghold, A
Dobnig, H
机构
[1] Karl Franzens Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria
[2] Karl Franzens Univ Graz, Dept Surg, Div Transplantat Surg, Graz, Austria
[3] Karl Franzens Univ Graz, Dept Radiol, Graz, Austria
[4] Karl Franzens Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria
关键词
osteoporosis; transplantation; immunosuppression; vertebral fractures; glucocorticoids; cylosporine A;
D O I
10.1016/S8756-3282(02)00926-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoprotegerin (OPG) is an antiresorptive cytokine and a key regulator of osteoclastogenesis and activity. Since OPG is downregulated by glucocorticoids and cyclosporine A in vitro we examined whether immunosuppressive therapy would play a role in the development of transplantation osteoporosis. We enrolled 57 cardiac transplant recipients (median time since transplantation, 3.2 years (1.1-11.5 years)) in this cross-sectional study. Standardized spinal X-rays as well as hip bone density measurements were performed in all patients. Serum OPG was determined using a commercially available ELISA. Vertebral fractures were present in 56% of the patients. Bone densities of all femoral neck subregions were correlated to serum OPG concentrations (r values between 0.40 and 0.48, all P < 0.005). Multiple regression analysis revealed OPG levels to be independently correlated to femoral neck Z scores (r = 0.49, P = 0.002). After adjustment for age, BMI, neck Z score, renal function, and months since transplantation, serum OPG was the only significant predictor of prevalent vertebral fractures (P = 0.001). In a separate 6-month prospective study of 14 heart transplant recipients receiving calcium and vitamin D serum OPG levels fell by 41% (P = 0.0004) after 3 months and 47% (P = 0.0001) after 6 months following cardiac transplantation. Bone loss at the lumbar spine and femoral neck after 6 months was correlated to the decrease in serum OPG at 6 months (r = 0.82, P < 0.0001, and r = 0.60, P = 0.02, respectively) as well as 3 months after cardiac transplantation (r = 0.65, P = 0.01, and r = 0.69, P = 0.006, respectively). Serum OPG alone accounted for 67% of the variance of lumbar spine bone density changes over the first 6 months posttansplantation. We conclude that serum OPG levels decline consistently in all patients following initiation of immunosuppressive therapy and are independently correlated with changes in bone density. We hypothesize that OPG plays a major role in the development of transplantation osteoporosis. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:96 / 106
页数:11
相关论文
共 50 条
[11]  
DELMAS PD, 1991, J BONE MINER RES, V6, P639
[12]   VERTEBRAL FRACTURE ASSESSMENT USING A SEMIQUANTITATIVE TECHNIQUE [J].
GENANT, HK ;
WU, CY ;
VANKUIJK, C ;
NEVITT, MC .
JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 (09) :1137-1148
[13]  
GILLARDBERGUER D, 1994, TRANSPL P, V26, P2649
[14]   High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry [J].
Glendenning, P ;
Kent, GH ;
Adler, BD ;
Matz, L ;
Watson, L ;
O'Driscoll, GJ ;
Hurley, DM .
CLINICAL ENDOCRINOLOGY, 1999, 50 (03) :347-355
[15]   Mechanisms of bone loss after cardiac transplantation [J].
Guo, CY ;
Johnson, A ;
Locke, TJ ;
Eastell, R .
BONE, 1998, 22 (03) :267-271
[16]   BONE-MINERAL LOSS AND RECOVERY AFTER CARDIAC TRANSPLANTATION [J].
HENDERSON, NK ;
SAMBROOK, PN ;
KELLY, PJ ;
MACDONALD, P ;
KEOGH, AM ;
SPRATT, P ;
EISMAN, JA .
LANCET, 1995, 346 (8979) :905-905
[17]   The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption [J].
Hofbauer, LC ;
Khosla, S ;
Dunstan, CR ;
Lacey, DL ;
Boyle, WJ ;
Riggs, BL .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (01) :2-12
[18]   Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis [J].
Hofbauer, LC ;
Gori, F ;
Riggs, BL ;
Lacey, DL ;
Dunstan, CR ;
Spelsberg, TC ;
Khosla, S .
ENDOCRINOLOGY, 1999, 140 (10) :4382-4389
[19]  
Hofbauer LC, 1999, J BONE MINER RES, V14, pS176
[20]  
Holt MI, 2001, J BONE MINER RES, V16, pS364